Although reports of hantavirus cases in France in May 2026 revive the trauma of the 2020 pandemic, experts emphasize that these two viruses are scientifically very distinct.
Low Transmissibility
Unlike SARS-CoV-2, hantavirus is not a conventional respiratory virus that causes pneumonia, but a disease that primarily leads to acute pulmonary edema or kidney injury. While the initial symptoms (fever, headaches, muscle aches) can first resemble flu, the biological mechanism of hantavirus rests on abnormal permeability of blood vessels. This makes it a disease structurally different from Covid-19.
On the other hand, hantavirus is characterized by clinical severity substantially higher than that of Covid-19, with a mortality rate that is particularly high, fluctuating between 30% and 60% for cardiopulmonary forms. However, this deadly character is limited by a very low contagion potential. While Covid-19 spread massively through aerosols, human-to-human transmission of hantavirus (specifically the Andes virus strain) remains marginal. It requires prolonged and extremely close contact, such as sharing a bed. The primary mode of contamination remains indirect, through inhalation of dust contaminated with rodent droppings.
What Scientific Knowledge?
One of the major differences lies in the state of research: in 2020, the world faced an emerging unknown virus, whereas hantaviruses have been identified and studied since the 1950s. Specialists already have diagnostic tests (PCR and serology) and a detailed understanding of infection reservoirs, often linked to forested or agricultural environments. This accumulated expertise allows health authorities, including the WHO, to reassure about the risk of large-scale spread.
In other words, the prospect of a world pandemic is considered extremely unlikely. Despite this historical knowledge, there is currently no globally validated vaccine or targeted treatment. Management mainly centers on treating symptoms in intensive care. Current research is exploring several avenues, from DNA vaccines to monoclonal antibody immunotherapy, while trying to limit the excessive inflammatory response that drives fatalities.
